The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic neuritis, according to a press release from Oculis.
If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies.
“We are excited to advance privosegtor in optic neuropathies to address the substantial unmet patient needs for neuroprotective therapies, with the potential to extend into retina and beyond,” Riad Sherif, MD, CEO of Oculis, told Healio.
The designation is supported by positive visual function results from the randomized,